Wheeling and dealing his way to a cancer drug pipeline, Gilead’s Dan O’Day crafts a rich, $805M deal to bag a preclinical I/O drug

Looking to leap into the front of an incipient race to develop anti-CCR8 drugs for cancer, Gilead has plunked down $120 million in cash and offered up to $685 million in a deal to land the development rights for a drug that’s proved quite effective — in mice. Gilead has…

Click to view original post